Valbiotis SA
PAR:ALVAL

Watchlist Manager
Valbiotis SA Logo
Valbiotis SA
PAR:ALVAL
Watchlist
Price: 0.73 EUR 4.43% Market Closed
Market Cap: €17.3m

Operating Margin

-2 411%
Current
Declining
by 415.2%
vs 3-y average of -1 995.8%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-2 411%
=
Operating Income
€-11.4m
/
Revenue
€472k

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-2 411%
=
Operating Income
€-11.4m
/
Revenue
€472k

Peer Comparison

Country Company Market Cap Operating
Margin
FR
Valbiotis SA
PAR:ALVAL
17m EUR
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
388.2B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
166.3B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.9B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
48.8B USD
Loading...

Market Distribution

Lower than 97% of companies in France
Percentile
3nd
Based on 2 333 companies
3nd percentile
-2 411%
Low
-17 526.7% — 1.3%
Typical Range
1.3% — 11.5%
High
11.5% — 89 700%
Distribution Statistics
France
Min -17 526.7%
30th Percentile 1.3%
Median 6.1%
70th Percentile 11.5%
Max 89 700%

Valbiotis SA
Glance View

Market Cap
17.3m EUR
Industry
Biotechnology

Valbiotis SA develops products and candidate drugs designed to prevent metabolic diseases. The company is headquartered in Perigny, Nouvelle-Aquitaine. The company went IPO on 2017-06-07. The firm specializes in developing nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients. The company seeks to develop solutions designed to prevent type 2 diabetes, NASH, (non-alcoholic steatohepatitis) and obesity and to offer nutritional support. The firm prevents disease by developing products that reduce the risk factors of irreversible chronic diseases. The company provides patient support through new-generation medical nutrition solutions containing patented substances with clinically proven effects. Its products are plant-based and undergo strict scientific and clinical tests in collaboration with academic research centers.

ALVAL Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-2 411%
=
Operating Income
€-11.4m
/
Revenue
€472k
What is Valbiotis SA's current Operating Margin?

The current Operating Margin for Valbiotis SA is -2 411%, which is below its 3-year median of -1 995.8%.

How has Operating Margin changed over time?

Over the last 3 years, Valbiotis SA’s Operating Margin has decreased from -1 268.4% to -2 411%. During this period, it reached a low of -5 956% on Dec 31, 2024 and a high of -151.7% on Dec 31, 2023.

Back to Top